Biovica International
2,48 SEK -5,7%Vær den første som følger denne virksomhed
Biovica International is a pharmaceutical company that focuses its research on cancer treatments. The company is developing methods for measuring cell proliferation, where the test is taken via blood samples. The tests analyze the risk for the development of the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main area of focus is within treatment of breast cancer. The company was founded in 2008 and is headquartered in Uppsala.
Omsætning
7,29 mio.
EBIT %
-1.740,05 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
BIOVIC B
Daglig lav / høj pris
2,465 / 2,785
SEK
Markedsværdi
208,46 mio. SEK
Aktieomsætning
125,4 t SEK
Volumen
50 t
Seneste videoer
Finanskalender
Ekstraordinær generalforsamling
15.07.2024
Delårsrapport
12.09.2024
Generalforsamling
17.09.2024
Delårsrapport
12.12.2024
Delårsrapport
13.03.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Anders Rylander Investment AB | 10,7 % | 16,9 % |
Avanza Pension | 6,9 % | 6,0 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Biovica International AB – Annual report for the financial year 2023/2024 published
Clarification of notice to extraordinary general meeting
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools